Literature for peptidase S08.039: PCSK9 peptidase

(References are filtered for relevance to Review. To remove the filter click here. See explanation.)

2024
1. Agarwala,A., Asim,R. and Ballantyne,C.M.
   Oral PCSK9 Inhibitors
   Curr Atheroscler Rep26, 147-152. PubMed  Europe PubMed DOI  V  I
2. Bao,X., Liang,Y., Chang,H., Cai,T., Feng,B., Gordon,K., Zhu,Y., Shi,H., He,Y. and Xie,L.
   Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside
   Signal Transduct Target Ther9, 13-13. PubMed  Europe PubMed DOI  V
3. Chong,S., Mu,G., Cen,X., Xiang,Q. and Cui,Y.
   Effects of PCSK9 on thrombosis and haemostasis in a variety of metabolic states: Lipids and beyond (Review)
   Int J Mol Med53, PubMed  Europe PubMed DOI  V
4. Grejtakova,D., Boronova,I., Bernasovska,J. and Bellosta,S.
   PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes
   Cardiovasc Drugs Ther PubMed  Europe PubMed DOI  V
5. Hassandokht Mashhadi,M., Taheri,F., Irani,S., Mesbah Mousavi,A., Mehri,A. and Javid,H.
   Current Understanding of PCSK9 and Its Relevance to Cancer Prognosis and Immune Therapy: A Review
   Iran J Pathol19, 1-9. PubMed  Europe PubMed DOI  V
6. Hoekstra,M. and Van Eck,M.
   Gene Editing for the Treatment of Hypercholesterolemia
   Curr Atheroscler Rep PubMed  Europe PubMed DOI  V
7. Hsu,C.Y., Abdulrahim,M.N., Mustafa,M.A., Omar,T.M., Balto,F., Pineda,I., Khudair,T.T., Ubaid,M. and Ali,M.S.
   The multifaceted role of PCSK9 in cancer pathogenesis, tumor immunity, and immunotherapy
   Med Oncol41, 202-202. PubMed  Europe PubMed DOI  V
8. Imaralu,O.E., Aluganti Narasimhulu,C., Singal,P.K. and Singla,D.K.
   Role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in diabetic complications
   Can J Physiol Pharmacol102, 14-25. PubMed  Europe PubMed DOI  V
9. Macvanin,M., Gluvic,Z., Klisic,A., Manojlovic,M., Suri,J., Rizzo,M. and Isenovic,E.
   The Link between miRNAs and PCKS9 in Atherosclerosis
   Curr Med Chem31, 6926-6956. PubMed  Europe PubMed DOI  V
10. Mahjoubin-Tehran,M., Rezaei,S., Santos,R.D., Jamialahmadi,T., AlMahmeed,W. and Sahebkar,A.
    Targeting PCSK9 as a key player in lipid metabolism: exploiting the therapeutic and biosensing potential of aptamers
    Lipids Health Dis23, 156-156. PubMed  Europe PubMed DOI  V
11. Ndoj,K., Meurs,A., Papaioannou,D., Bjune,K. and Zelcer,N.
    The low-density lipoprotein receptor: Emerging post-transcriptional regulatory mechanisms
    Atherosclerosis401, 119082-119082. PubMed  Europe PubMed DOI  V
12. Testa,G., Giannelli,S., Staurenghi,E., Cecci,R., Floro,L., Gamba,P., Sottero,B. and Leonarduzzi,G.
    The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer's Disease: A Possible Target for the Disease Treatment
    Int J Mol Sci25, PubMed  Europe PubMed DOI  V
13. Zendjebil,S. and Steg,P.G.
    PCSK9 Monoclonal Antibodies Have Come a Long Way
    Curr Atheroscler Rep26, 721-732. PubMed  Europe PubMed DOI  V
14. Zhu,X.B., Xu,Y.Y., Li,L.C., Sun,J.B., Wang,Y.Z., Chen,J., Wang,C., Zhang,S. and Jin,L.Y.
    Function of proprotein convertase subtilisin/kexin type 9 and its role in central nervous system diseases: An update on clinical evidence
    Drug Dev Res85, e22131-e22131. PubMed  Europe PubMed DOI  V
2023
15. Bell,A.S., Wagner,J., Rosoff,D.B. and Lohoff,F.W.
    Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system
    Neurosci Biobehav Rev149, 105155-105155. PubMed  Europe PubMed DOI  V
16. Cendron,L., Rothenberger,S., Cassari,L., Dettin,M. and Pasquato,A.
    Proprotein convertases regulate trafficking and maturation of key proteins within the secretory pathway
    Adv Protein Chem Struct Biol133, 1-54. PubMed  Europe PubMed DOI  V
17. Chan,D.C. and Watts,G.F.
    The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies
    Clin Ther45, 1034-1046. PubMed  Europe PubMed DOI  K  V
18. Hummelgaard,S., Vilstrup,J.P., Gustafsen,C., Glerup,S. and Weyer,K.
    Targeting PCSK9 to tackle cardiovascular disease
    Pharmacol Ther249, 108480-108480. PubMed  Europe PubMed DOI  V
19. Jaafar,A.K., Techer,R., Chemello,K., Lambert,G. and Bourane,S.
    PCSK9 and the nervous system: a no-brainer?
    J Lipid Res64, 100426-100426. PubMed  Europe PubMed DOI  V
20. Mohamed,F., Mansfield,B. and Raal,F.J.
    Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
    J Clin Med12, PubMed  Europe PubMed DOI  V
21. Oostveen,R.F., Khera,A.V., Kathiresan,S., Stroes,E.S.G., Fitzgerald,K., Harms,M.J., Oakes,B.L. and Kastelein,J.J.P.
    New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing
    Arterioscler Thromb Vasc Biol43, 1081-1092. PubMed  Europe PubMed DOI  V
22. Rikhi,R. and Shapiro,M.D.
    Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control
    Eur Cardiol18, e45-e45. PubMed  Europe PubMed DOI  V
23. Sener,Y.Z. and Tokgozoglu,L.
    Pleiotropy of PCSK9: Functions in Extrahepatic Tissues
    Curr Cardiol Rep25, 979-985. PubMed  Europe PubMed DOI  V
24. Singh,S., Sharma,H., Ramankutty,R., Ramaswamy,S. and Agrawal,N.
    Natural Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Review
    Comb Chem High Throughput Screen26, 2668-2678. PubMed  Europe PubMed DOI  V
25. Wang,Y., Fang,D., Yang,Q., You,J., Wang,L., Wu,J., Zeng,M. and Luo,M.
    Interactions between PCSK9 and NLRP3 inflammasome signaling in atherosclerosis
    Front Immunol14, 1126823-1126823. PubMed  Europe PubMed DOI  V
26. Xu,J.N., Wang,T.T., Shu,H., Shi,S.Y., Tao,L.C. and Li,J.J.
    Insight into the role of PCSK9 in glucose metabolism
    Clin Chim Acta547, 117444-117444. PubMed  Europe PubMed DOI  V
2022
27. Ahamad,S., Mathew,S., Khan,W.A. and Mohanan,K.
    Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia
    Drug Discov Today27, 1332-1349. PubMed  Europe PubMed DOI  V
28. Cammisotto,V., Baratta,F., Simeone,P.G., Barale,C., Lupia,E., Galardo,G., Santilli,F., Russo,I. and Pignatelli,P.
    Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis
    Antioxidants (Basel)11, PubMed  Europe PubMed DOI  V
29. Katzmann,J.L., Cupido,A.J. and Laufs,U.
    Gene Therapy Targeting PCSK9
    Metabolites12, PubMed  Europe PubMed DOI  K  V
30. Kuzmich,N., Andresyuk,E., Porozov,Y., Tarasov,V., Samsonov,M., Preferanskaya,N., Veselov,V. and Alyautdin,R.
    PCSK9 as a Target for Development of a New Generation of Hypolipidemic Drugs
    Molecules27, PubMed  Europe PubMed DOI  V
31. Liu,C., Chen,J., Chen,H., Zhang,T., He,D., Luo,Q., Chi,J., Hong,Z., Liao,Y., Zhang,S., Wu,Q., Cen,H., Chen,G., Li,J. and Wang,L.
    PCSK9 Inhibition: From Current Advances to Evolving Future
    Cells11, PubMed  Europe PubMed DOI  V
32. Mbikay,M. and Chretien,M.
    The Biological Relevance of PCSK9: When Less Is Better.
    Biochem Cell Biol100, 189-198. PubMed  Europe PubMed DOI  V
33. Puteri,M.U., Azmi,N.U., Ridwan,S., Iqbal,M., Fatimah,T., Rini,T.D.P., Kato,M. and Saputri,F.C.
    Recent Update on PCSK9 and Platelet Activation Experimental Research Methods: In Vitro and In Vivo Studies
    J Cardiovasc Dev Dis9, PubMed  Europe PubMed DOI  V
34. Seidah,N.G. and Garcon,D.
    Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond
    Curr Atheroscler Rep24, 821-830. PubMed  Europe PubMed DOI  K  V
35. Zulkapli,R., Yusof,M.Y.P.M., Abd Muid,S., Wang,S.M., Firus Khan,A.Y. and Nawawi,H.
    A Systematic Review on Attenuation of PCSK9 in Relation to Atherogenesis Biomarkers Associated with Natural Products or Plant Bioactive Compounds in In Vitro Studies: A Critique on the Quality and Imprecision of Studies
    Int J Environ Res Public Health19, PubMed  Europe PubMed DOI  V
2021
36. Banerjee,Y., Pantea Stoian,A., Cicero,A.F.G., Fogacci,F., Nikolic,D., Sachinidis,A., Rizvi,A.A., Janez,A. and Rizzo,M.
    Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia
    Expert Opin Drug Saf1-12. PubMed  Europe PubMed DOI  V
37. Bhattacharya,A., Chowdhury,A., Chaudhury,K. and Shukla,P.C.
    Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer
    Biochim Biophys Acta Rev Cancer1876, 188581-188581. PubMed  Europe PubMed DOI  V
38. Gencer,B. and Mach,F.
    PCSK9 inhibition could be effective for acute myocardial infarction
    Curr Med Chem PubMed  Europe PubMed DOI  V
39. Mahboobnia,K., Pirro,M., Marini,E., Grignani,F., Bezsonov,E.E., Jamialahmadi,T. and Sahebkar,A.
    PCSK9 and cancer: Rethinking the link
    Biomed Pharmacother140, 111758-111758. PubMed  Europe PubMed DOI  K  V
40. Sundararaman,S.S., Doring,Y. and van der Vorst,E.P.C.
    PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology
    Biomedicines9, PubMed  Europe PubMed DOI  V
41. Xiang,Q., Liu,W., Zeng,J., Deng,Y., Peng,J., Liu,H., Ren,Z., Jiang,Z., Liu,L. and Tang,Z.
    Effect of PCSK9 on Vascular Smooth Muscle Cell Functions: A New Player in Atherosclerosis
    Curr Med Chem28, 7446-7460. PubMed  Europe PubMed DOI  V
2020
42. Andreadou,I., Tsoumani,M., Vilahur,G., Ikonomidis,I., Badimon,L., Varga,Z.V., Ferdinandy,P. and Schulz,R.
    PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation
    Front Physiol11, 602497-602497. PubMed  Europe PubMed DOI  V
43. Furtado,R.H.M. and Giugliano,R.P.
    What lessons have we learned and what remains to be clarified for PCSK9 inhibitors? A review of FOURIER and ODYSSEY outcomes trials
    Cardiol Ther9, 59-73. PubMed  Europe PubMed DOI  V
44. Guo,Y., Yan,B., Tai,S., Zhou,S. and Zheng,X.L.
    PCSK9: Associated with cardiac diseases and their risk factors?
    Arch Biochem Biophys108717-108717. PubMed  Europe PubMed DOI  V
45. O'Connell,E.M. and Lohoff,F.W.
    Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders
    Front Neurosci14, 609-609. PubMed  Europe PubMed DOI  V
46. Rakipovski,G., Hovingh,G.K. and Nyberg,M.
    Proprotein convertase subtilisin/kexin type 9 inhibition as the next statin?
    Curr Opin Lipidol PubMed  Europe PubMed DOI  V
47. Schluter,K.D., Wolf,A. and Schreckenberg,R.
    Coming Back to Physiology: Extra Hepatic Functions of Proprotein Convertase Subtilisin/Kexin Type 9
    Front Physiol11, 598649-598649. PubMed  Europe PubMed DOI  V
48. Sinning,D. and Landmesser,U.
    Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
    Curr Cardiol Rep22, 176-176. PubMed  Europe PubMed DOI  V
49. Wu,Y.X. and Wang,Y.
    [Progress on the molecular mechanisms of PCSK9-mediated degradation of low density lipoprotein receptor]
    Yi Chuan42, 965-978. PubMed  Europe PubMed DOI  V
50. Ye,Q., Svatikova,A., Meeusen,J.W., Kludtke,E.L. and Kopecky,S.L.
    Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Plasma Ceramide Levels
    Am J Cardiol128, 163-167. PubMed  Europe PubMed DOI  V
51. Yuan,Y., Wu,W., Sun,S., Zhang,Y. and Chen,Z.
    PCSK9: A Potential Therapeutic Target for Sepsis
    J Immunol Res2020, 2687692-2687692. PubMed  Europe PubMed DOI  V
52. Yurtseven,E., Ural,D., Baysal,K. and Tokgozoglu,L.
    An Update on the Role of PCSK9 in Atherosclerosis
    J Atheroscler Thromb27, 909-918. PubMed  Europe PubMed DOI  V
2018
53. Karagiannis,A.D., Liu,M., Toth,P.P., Zhao,S., Agrawal,D.K., Libby,P. and Chatzizisis,Y.S.
    Pleiotropic anti-atherosclerotic effects of PCSK9 inhibitors from molecular biology to clinical translation
    Curr Atheroscler Rep20, 20-20. PubMed  Europe PubMed DOI  V
54. Pettersen,D. and Fjellstrom,O.
    Small molecule modulators of PCSK9 - a literature and patent overview
    Bioorg Med Chem Lett28, 1155-1160. PubMed  Europe PubMed DOI  V  I
55. Stoekenbroek,R.M. and Kastelein,J.J.P.
    Proprotein convertase subtilisin/kexin type 9: from genetics to clinical trials
    Curr Opin Cardiol33, 269-275. PubMed  Europe PubMed DOI  V
2017
56. El Khoury,P., Elbitar,S., Ghaleb,Y., Khalil,Y.A., Varret,M., Boileau,C. and Abifadel,M.
    PCSK9 Mutations in familial hypercholesterolemia: from a groundbreaking discovery to anti-PCSK9 therapies
    Curr Atheroscler Rep19, 49-49. PubMed  Europe PubMed DOI  M  V
57. Preiss,D. and Mafham,M.
    PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
    Diabetologia60, 381-389. PubMed  Europe PubMed DOI  V
58. Scherer,D.J., Nelson,A.J., Psaltis,P.J. and Nicholls,S.J.
    Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors
    Intern Med J47, 856-865. PubMed  Europe PubMed DOI  V
2016
59. Maluch,I., Walewska,A., Sikorska,E. and Prahl,A.
    [Proprotein convertases - family of serine proteases with a broad spectrum of physiological functions]
    Postepy Biochem62, 472-481. PubMed  Europe PubMed  V
60. McDonagh,M., Peterson,K., Holzhammer,B. and Fazio,S.
    A systematic review of PCSK9 inhibitors alirocumab and evolocumab
    J Manag Care Spec Pharm22, 641-653. PubMed  Europe PubMed DOI  V
61. Zhang,L., Song,K., Zhu,M., Shi,J., Zhang,H., Xu,L. and Chen,Y.
    Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke
    Int J Neurosci126, 675-680. PubMed  Europe PubMed DOI  V
2015
62. Jialal,I. and Patel,S.B.
    PCSK9 inhibitors: the next frontier in low-density lipoprotein lowering
    Metab Syndr Relat Disord13, 99-101. PubMed  Europe PubMed DOI  V
63. Schulz,R., Schluter,K.D. and Laufs,U.
    Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
    Basic Res Cardiol110, 4-4. PubMed  Europe PubMed DOI  V
64. Stawowy,P.
    Proprotein convertases in atherogenesis
    Curr Opin Lipidol26, 338-344. PubMed  Europe PubMed DOI  V
65. Tavori,H., Giunzioni,I. and Fazio,S.
    PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9
    Curr Opin Endocrinol Diabetes Obes22, 126-132. PubMed  Europe PubMed DOI  V
66. Zhang,X.L., Zhu,Q.Q., Zhu,L., Chen,J.Z., Chen,Q.H., Li,G.N., Xie,J., Kang,L.N. and Xu,B.
    Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
    BMC Med13, 123-123. PubMed  Europe PubMed DOI  V
2014
67. Abifadel,M., Elbitar,S., El Khoury,P., Ghaleb,Y., Chemaly,M., Moussalli,M.L., Rabes,J.P., Varret,M. and Boileau,C.
    Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs
    Curr Atheroscler Rep16, 439-439. PubMed  Europe PubMed DOI  V
68. Wu,Q., Tang,Z.H., Peng,J., Liao,L., Pan,L.H., Wu,C.Y., Jiang,Z.S., Wang,G.X. and Liu,L.S.
    The dual behavior of PCSK9 in the regulation of apoptosis is crucial in Alzheimer's disease progression (Review)
    Biomed Rep2, 167-171. PubMed  Europe PubMed DOI  V
2013
69. Poirier,S. and Mayer,G.
    The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol
    Drug Des Devel Ther7, 1135-1148. PubMed  Europe PubMed DOI  V
70. Seidah,N.G., Sadr,M.S., Chretien,M. and Mbikay,M.
    The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions
    J Biol Chem288, 21473-21481. PubMed  Europe PubMed DOI  V
71. Willrich,M.A. and Baudhuin,L.M.
    PCSK9 and the road less traveled: how an unconventional approach led to a major discovery
    Clin Chem59, 1283-1284. PubMed  Europe PubMed  V
2012
72. Lambert,G., Sjouke,B., Choque,B., Kastelein,J.J. and Hovingh,G.K.
    The PCSK9 decade
    J Lipid Res53, 2515-2524. PubMed  Europe PubMed DOI  V
73. Seidah,N.G. and Prat,A.
    The biology and therapeutic targeting of the proprotein convertases
    Nat Rev Drug Discov11, 367-383. PubMed  Europe PubMed DOI  V
2011
74. Cariou,B., Le May,C. and Costet,P.
    Clinical aspects of PCSK9
    Atherosclerosis216, 258-265. PubMed  Europe PubMed DOI  M  V
75. Seidah,N.G.
    The proprotein convertases, 20 years later
    Methods Mol Biol768, 23-57. PubMed  Europe PubMed DOI  V
76. Seidah,N.G.
    What lies ahead for the proprotein convertases?
    Ann N Y Acad Sci1220, 149-161. PubMed  Europe PubMed DOI  V
77. Tibolla,G., Norata,G.D., Artali,R., Meneghetti,F. and Catapano,A.L.
    Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition
    Nutr Metab Cardiovasc Dis21, 835-843. PubMed  Europe PubMed DOI  V  I
2009
78. Hedrick,J.A.
    Targeting PCSK9 for the treatment of hypercholesterolemia
    Curr Opin Investig Drugs10, 938-946. PubMed  Europe PubMed  V
79. Lambert,G., Charlton,F., Rye,K.A. and Piper,D.E.
    Molecular basis of PCSK9 function
    Atherosclerosis203, 1-7. PubMed  Europe PubMed DOI  V  T
80. Li,H., Li,H., Ziegler,N., Cui,R. and Liu,J.
    Recent patents on PCSK9: a new target for treating hypercholesterolemia
    Recent Pat DNA Gene Seq3, 201-212. PubMed  Europe PubMed DOI  V
81. Seidah,N.G.
    PCSK9 as a therapeutic target of dyslipidemia
    Expert Opin Ther Targets13, 19-28. PubMed  Europe PubMed DOI  V
2008
82. Calandra,S. and Tarugi,P.
    Genetics and molecular biology: proprotein convertase subtilisin/kexin type 9 and LDL receptor - an intriguing story
    Curr Opin Lipidol19, 208-211. PubMed  Europe PubMed DOI  V
83. Costet,P., Krempf,M. and Cariou,B.
    PCSK9 and LDL cholesterol: unravelling the target to design the bullet
    Trends Biochem Sci33, 426-434. PubMed  Europe PubMed DOI  V
84. Lopez,D.
    PCSK9: an enigmatic protease
    Biochim Biophys Acta1781, 184-191. PubMed  Europe PubMed DOI  V
2007
85. Horton,J.D., Cohen,J.C. and Hobbs,H.H.
    Molecular biology of PCSK9: its role in LDL metabolism
    Trends Biochem Sci32, 71-77. PubMed  Europe PubMed DOI  V
86. Lambert,G.
    Unravelling the functional significance of PCSK9
    Curr Opin Lipidol18, 304-309. PubMed  Europe PubMed DOI  V
87. Seidah,N.G. and Prat,A.
    The proprotein convertases are potential targets in the treatment of dyslipidemia
    J Mol Med (Berl)85, 685-696. PubMed  Europe PubMed DOI  V
2006
88. Scamuffa,N., Calvo,F., Chretien,M., Seidah,N.G. and Khatib,A.M.
    Proprotein convertases: lessons from knockouts
    FASEB J20, 1954-1963. PubMed  Europe PubMed DOI  K  V
89. Seidah,N.G., Khatib,A.M. and Prat,A.
    The proprotein convertases and their implication in sterol and/or lipid metabolism
    Biol Chem387, 871-877. PubMed  Europe PubMed DOI  V